It is likely that in future in addition to the currently available treatment regimens one could employ VNS and alpha7nAChR agonists, stable and synthetic analogues of lipoxins, resolvins, protectins and maresins in the management of RA, lupus, inflammatory bowel diseases and other inflammatory and autoimmune disorders. The gene discussed is CD59; the disease is rheumatoid arthritis.